Clinical trials: Cancer Disease Progression
Metastatic Breast Cancer
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast…
- Trial name
- NCT05068726
- Testing
- 18F Fluoroestradiol Radiopharmaceutical with PET/CT
- Where
- 24 sites in United States
- Volunteers
- 51 people
- Sponsor
- GE Healthcare
Neuroendocrine Tumor, Carcinoid
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems.
- Conditions
- Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
- Trial name
- RegisterNET (NCT02270567)
- Testing
- NETest
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Solid Tumor
Solid Tumors Using Ixabepilone and Dasatinib
Patients are being asked to take part in this study because they have been diagnosed with an advanced solid tumor that is not responding to standard treatments.
- Trial name
- NCT00717704
- Testing
- ixabepilone, Dasatinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Medstar Health Research Institute
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].
- Trial name
- VERU-024 (NCT05065411)
- Testing
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Where
- 30 sites in United States
- Volunteers
- 5 people
- Sponsor
- Veru Inc.
Lung Adenocarcinoma, EGFR Activating Mutation
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
To compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients gradually progressed from first-line EGFR-TKI treatment.
- Trial name
- NCT03544814
- Testing
- icotinib combined with pemetrexed plus cisplatin, first icotinib and then pemetrexed plus cisplatin
- Volunteers
- 99 people
- Sponsor
- Shanghai Chest Hospital
Bladder Cancer
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
- Trial name
- NCT01284205
- Testing
- Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
- Where
- 14 sites in United States
- Sponsor
- Bioniche Life Sciences Inc.
Diabetes Mellitus, Type 1
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
This will be a study conducted as a placebo-controlled, double blind, 1:1 randomized controlled clinical trial testing a Tumor Necrosis Factor Blocker (Anti-TNFα) substance versus placebo in subjects with a 2-year 50% risk of…
- Trial name
- NCT04729296
- Testing
- Golimumab
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-small Cell Lung Cancer, Prostate Cancer
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen…
- Conditions
- Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer, Transitional Cell Carcinoma
- Trial name
- NCT03927573
- Testing
- GEM3PSCA
- Where
- 5 sites in Germany
- Volunteers
- 23 people
- Sponsor
- AvenCell Europe GmbH
Lung Cancer
Progression of Untreated Pulmonary Ground Glass Opacity
In this study, about 2000 GGO patients will be included for a 5-year follow-up. The aim of this study is to elucidate the biological nature of pulmonary GGO lesion and provide evidence for GGO treatment.
- Trial name
- NCT03723629
- Testing
- No intercention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
This single arm study will assess progression-free survival, feasibility of use and safety of Avastin in combination with 5-FU/FA, oxaliplatin and irinotecan (FOLFOXIRI) as first line treatment in patients with metastatic…
- Trial name
- NCT00940303
- Testing
- 5-FU, bevacizumab [Avastin], irinotecan
- Where
- 17 sites in Germany
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression
Molecular pathology of Colorectal Cancer: Investigating the role of novel molecular profiles, microRNA's and their targets in Colorectal Cancer progression
- Trial name
- NCT03309722
- Testing
- biomarker study
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Southampton
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00899353
- Testing
- Omega 3 Fatty Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marshall University
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior…
- Trial name
- NCT00391092
- Testing
- bevacizumab [Avastin], Docetaxel, Herceptin
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
The goal of this prospective observational study is to evaluate how well a previously developed prediction model can estimate outcomes in adults with gastric cancer.
- Trial name
- NCT07776067
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced NSCLC
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
- Trial name
- NCT06924606
- Testing
- JS207 injection +docetaxel, JS207 injection +JS004 injection, JS207 injection
- Where
- 18 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Progression Free Survival
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer.
- Trial name
- NCT02959749
- Testing
- Osimertinib, docetaxel, bevacizumab
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Qingdao Central Hospital
Prostate Cancer
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer…
- Trial name
- NCT00659438
- Testing
- ZD6474 (Vandetanib), Bicalutamide
- Where
- 5 sites in France
- Volunteers
- 95 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Breast Cancer
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
This Phase Ⅱ study was designed to assess the efficacy and safety of the combination of tucidinostat, angiogenesis inhibitors and fulvestrant for advanced HR-positive, HER2-negative breast cancer patients after the failure of…
- Trial name
- NCT06750848
- Testing
- Chidamide，Fulvestrant，angiogenesis inhibitors
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jundong Wu
Head and Neck Cancer
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had…
- Trial name
- NCT00617734
- Testing
- IMC-A12 (cixutumumab), cetuximab (Erbitux ®)
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.